Low Maternal Thyroid Hormone During Pregnancy Increases Risk For Schizophrenia In Offspring
Reports new study in Biological Psychiatry
Reports new study in Biological Psychiatry
Philadelphia, PA, June 21, 2016
A study published in Biological Psychiatry reveals a new link between low levels of the thyroid hormone thyroxine during pregnancy and risk of schizophrenia in the offspring.
Low levels of free thyroxine in pregnant women, referred to as hypothyroxinemia, are associated with abnormalities in cognitive development similar to those in schizophrenia, a neurodevelopmental disorder. Hypothyroxinemia is also associated with preterm birth, a risk factor for schizophrenia.
To determine if hypothyroxinemia is associated with schizophrenia, the study, led by senior author Dr. Alan Brown, Professor of Psychiatry Epidemiology at Columbia University Medical Center, the New York State Psychiatric Institute, and Columbia University’s Mailman School of Public Health, examined thyroxine levels in archived serum samples from 1010 mothers of children with schizophrenia and 1010 matched control mothers. The sera were collected during the first and early second trimesters of pregnancy as part of the Finnish Maternity Cohort. Comprehensive Finnish registries of the population and psychiatric diagnoses provided information on case status (schizophrenia or control) among offspring of mothers corresponding to the prenatal serum samples.
The authors found that 11.8% of people with schizophrenia had a mother with hypothyroxinemia, compared with 8.6% of people without schizophrenia. The finding was statistically significant. This suggests that children of mothers with hypothyroxinemia during pregnancy have increased odds of developing schizophrenia. The association remained even after adjusting for variables strongly related to schizophrenia such as maternal psychiatric history and smoking.
First author of the study Dr. David Gyllenberg of the University of Turku, Finland, thinks the importance of this paper is that it “links the finding to an extensive literature on maternal hypothyroxinemia during gestation altering offspring brain development.” Dr. Gyllenberg was a visiting scholar at Columbia University when much of the research was conducted.
Brown emphasized that "this work adds to a body of literature suggesting that maternal influences, both environmental and genetic, contribute to the risk of schizophrenia. Although replication in independent studies is required before firm conclusions can be drawn, the study was based on a national birth cohort with a large sample size, increasing the plausibility of the findings."
This study did not address the cause of this association, but did find that adjusting for preterm birth lessened the association between hypothyroxinemia and schizophrenia, suggesting that preterm birth may mediate some of the increased risk.
The authors note in the paper that the finding may not be specific to schizophrenia, and should be studied as a risk factor for other neurodevelopmental disorders as well, such as bipolar disorder and autism. The finding is expected to stimulate further studies examining how hypothyroxinemia causes neurodevelopmental abnormalities and ultimately contributes to risk of mental illnesses that arise during development.
“As rodent models of maternal hypothyroxinemia have been developed and schizophrenia is largely considered a disorder of brain development, I hope this paper can inform future animal studies examining molecular and cellular deviations that are relevant to schizophrenia,” said Gyllenberg.
Dr. John Krystal, Editor of Biological Psychiatry, thinks the association has clinical potential for reducing risk in the offspring of mothers with low thyroxine levels. “This study identifies a preventable potential contributor to the risk for schizophrenia. Maternal hypothyroidism can be easily diagnosed and effectively treated,” said Krystal.
Notes for editors
The article is "Hypothyroxinemia During Gestation and Offspring Schizophrenia in a National Birth Cohort," by David Gyllenberg, Andre Sourander, Heljä-Marja Surcel, Susanna Hinkka-Yli-Salomäki, Ian W. McKeague, and Alan S. Brown (doi: 10.1016/j.biopsych.2015.06.014). It appears in Biological Psychiatry, volume 79, issue 12 (2016), published by Elsevier.
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact David Gyllenberg at email@example.com or Alan Brown at firstname.lastname@example.org.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th out of 140 Psychiatry titles and 10th out of 252 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2014 Impact Factor score for Biological Psychiatry is 10.255.
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
Editorial Office, Biological Psychiatry
+1 214 648 0880